E2906 – Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years)
***Patient enrollment to trial E2906 was suspended on February 23, 2015.***
Physician and Research Staff Educational Materials:
These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.
- Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.
Information and Assistance from the National Cancer Institute:
- Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.
Additional Information on ClinicalTrials.gov: Displayed below is an interactive view of the study record as it appears in the government registry. If you are experiencing technical difficulties with this view, visit clinicaltrials.gov and search for record NCT01041703.